On February 2nd, the IP-SAFE project, spearheaded by the Institute of Modern Physics under the Chinese Academy of Sciences, successfully wrapped up the principal installation of its accelerator device in the Lanzhou New Area. This achievement signifies a pivotal advancement in the construction of the world's inaugural demonstration facility dedicated to the mass production of alpha medical isotopes, leveraging a superconducting linear accelerator. It establishes a robust groundwork for the project's overall completion.
The IP-SAFE project, formally known as the "Accelerator-Based Medical Isotope Drug Research and Development Platform," stands as a cornerstone initiative within China's national science and education infrastructure blueprint for the 14th Five-Year Plan era. Its overarching goal is to facilitate the large-scale production of medical alpha isotopes, including actinium-225 and radium-223. By doing so, it aims to dismantle China's enduring dependence on imported high-end medical nuclides.